Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer|Esophagus Cancer|Lung Cancer, Nonsmall Cell|Squamous Cell Carcinoma of the Head and Neck
DRUG: Tisotumab Vedotin
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE), An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment emergent adverse event (TEAE) is an AE occurring on or after the first dose of study medication or worsening during treatment period., Day 1 to Week 24 plus 30 days
Objective Response Rate, Objective Response was investigator-assessed based on the Response Evaluation Criteria In Solid Tumors version 1.1 \[RECIST 1.1\] criteria. The best overall response was reported for each participant., Day 1 to Week 24 plus 30 days|Number of Participants With Increased Cancer Antigen (CA 125) Levels, The number of participants with ovarian cancer whose levels of CA125 Antigen had increased since the end of the base trial are presented., Day 1 to Week 24 plus 30 days|Number of Participants With Increased Prostate Specific Antigen (PSA), The number of participants with prostate cancer whose levels of PSA had increased since the end of the base trial are presented., Day 1 to Week 24 plus 30 days
This is an open-label, multicenter trial to collect long-term safety and efficacy data and to provide ongoing access to tisotumab vedotin for patients with solid tumors who have completed a tisotumab vedotin base trial.